Literature DB >> 26897241

Spotlight on esophageal perforation: A multinational study using the Pittsburgh esophageal perforation severity scoring system.

Michael Schweigert1, Hugo Santos Sousa2, Norbert Solymosi3, Aleksandar Yankulov4, Marta Jiménez Fernández5, Rory Beattie6, Attila Dubecz7, Charlotte Rabl8, Simon Law9, Daniel Tong10, Danail Petrov11, Annemaria Schäbitz12, Rudolf J Stadlhuber8, Julia Gumpp11, Dietmar Ofner8, Jim McGuigan6, José Costa-Maia2, Helmut Witzigmann12, Hubert J Stein7.   

Abstract

OBJECTIVE: The Pittsburgh group has suggested a perforation severity score (PSS) for better decision making in the management of esophageal perforation. Our study aim was to determine whether the PSS can be used to stratify patients with esophageal perforation into distinct subgroups with differential outcomes in an independent study population.
METHODS: In a retrospective study cases of esophageal perforation were collected (study-period, 1990-2014). The PSS was analyzed using logistic regression as a continuous variable and stratified into low, intermediate, and high score groups.
RESULTS: Data for 288 patients (mean age, 59.9 years) presenting with esophageal perforation (during the period 1990-2014) were abstracted. Etiology was spontaneous (Boerhaave; n = 119), iatrogenic (instrumentation; n = 85), and traumatic perforation (n = 84). Forty-three patients had coexisting esophageal cancer. The mean PSS was 5.82, and was significantly higher in patients with fatal outcome (n = 57; 19.8%; mean PSS, 9.79 vs 4.84; P < .001). Mean PSS was also significantly higher in patients receiving operative management (n = 200; 69%; mean PSS, 6.44 vs 4.40; P < .001). Using the Pittsburgh strata, patients were assigned to low PSS (≤2; n = 63), intermediate PSS (3-5; n = 86), and high PSS (>5; n = 120) groups. Perforation-related morbidity, length of stay, frequency of operative treatment, and mortality increased with increasing PSS strata. Patients with high PSS were 3.37 times more likely to have operative management compared with low PSS.
CONCLUSIONS: The Pittsburgh PSS reliably reflects the seriousness of esophageal perforation and stratifies patients into low-, intermediate-, and high-risk groups with differential morbidity and mortality outcomes.
Copyright © 2016 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  esophageal perforation; esophagus; foregut surgery; sepsis

Mesh:

Year:  2015        PMID: 26897241     DOI: 10.1016/j.jtcvs.2015.11.055

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  14 in total

1.  Outcome of stent grafting for esophageal perforations: single-center experience.

Authors:  Fausto Biancari; Tuomas Tauriainen; Tatu Ylikotila; Misa Kokkonen; Jukka Rintala; Elisa Mäkäräinen-Uhlbäck; Vesa Koivukangas; Juha Saarnio
Journal:  Surg Endosc       Date:  2017-01-11       Impact factor: 4.584

2.  Minimally invasive surgical management of spontaneous esophageal perforation (Boerhaave's syndrome).

Authors:  Jessie A Elliott; Louise Buckley; Mohamed Albagir; Antonios Athanasiou; Thomas J Murphy
Journal:  Surg Endosc       Date:  2019-05-29       Impact factor: 4.584

3.  Does the Pittsburgh Severity Score Predict Patients' Outcomes in Benign Esophageal Perforations?

Authors:  Erika Andreatta; Andrea Lovece; Valentina Milani; Emanuele Asti; Luigi Bonavina
Journal:  J Gastrointest Surg       Date:  2022-02-28       Impact factor: 3.267

4.  Early diagnosis is associated with improved clinical outcomes in benign esophageal perforation: an individual patient data meta-analysis.

Authors:  Bram D Vermeulen; Britt van der Leeden; Jawad T Ali; Tomas Gudbjartsson; Michael Hermansson; Donald E Low; Douglas G Adler; Abraham J Botha; Xavier B D'Journo; Atila Eroglu; Lorenzo E Ferri; Christoph Gubler; Jan Willem Haveman; Lileswar Kaman; Richard A Kozarek; Simon Law; Gunnar Loske; Joerg Lindenmann; Jung-Hoon Park; J David Richardson; Paulina Salminen; Ho-Yong Song; Jon A Søreide; Manon C W Spaander; Jeffrey N Tarascio; Jon A Tsai; Tim Vanuytsel; Camiel Rosman; Peter D Siersema
Journal:  Surg Endosc       Date:  2020-07-17       Impact factor: 4.584

5.  Suitable Diagnosis and Treatment of Esophageal Ruptures in Cases of Non-Boerhaave Syndrome: A Comparison With Boerhaave Syndrome.

Authors:  Shunsuke Hayakawa; Ryo Ogawa; Sunao Ito; Seiichi Nakaya; Tomotaka Okubo; Hiroyuki Sagawa; Tatsuya Tanaka; Hiroki Takahashi; Yoichi Matsuo; Shuji Takiguchi
Journal:  J Investig Med High Impact Case Rep       Date:  2021 Jan-Dec

6.  Ligamentum arteriosum calcification that presented as an esophageal perforation caused by duck bone ingestion.

Authors:  Xiang-Yu Chu; Yong Cui; Zhi Gao
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

7.  Primary repair of esophageal perforation: Case report.

Authors:  Akello W Abila; Mburu E Nditika; Rono D Kipkemoi; Stephen Ondigo; Barasa O Khwa-Otsyula
Journal:  Int J Surg Case Rep       Date:  2020-05-11

8.  Primary and Rescue Endoluminal Vacuum Therapy in the Management of Esophageal Perforations and Leaks.

Authors:  Sasha Still; Marissa Mencio; Estrellita Ontiveros; James Burdick; Steven G Leeds
Journal:  Ann Thorac Cardiovasc Surg       Date:  2018-06-07       Impact factor: 1.520

Review 9.  Esophageal emergencies: WSES guidelines.

Authors:  Mircea Chirica; Michael D Kelly; Stefano Siboni; Alberto Aiolfi; Carlo Galdino Riva; Emanuele Asti; Davide Ferrari; Ari Leppäniemi; Richard P G Ten Broek; Pierre Yves Brichon; Yoram Kluger; Gustavo Pereira Fraga; Gil Frey; Nelson Adami Andreollo; Federico Coccolini; Cristina Frattini; Ernest E Moore; Osvaldo Chiara; Salomone Di Saverio; Massimo Sartelli; Dieter Weber; Luca Ansaloni; Walter Biffl; Helene Corte; Imtaz Wani; Gianluca Baiocchi; Pierre Cattan; Fausto Catena; Luigi Bonavina
Journal:  World J Emerg Surg       Date:  2019-05-31       Impact factor: 5.469

Review 10.  Esophageal Stenting in Clinical Practice: an Overview.

Authors:  Bram D Vermeulen; Peter D Siersema
Journal:  Curr Treat Options Gastroenterol       Date:  2018-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.